ipilimumab
Showing 901 - 914 of 914
Kidney Cancer Trial run by the CC (ipilimumab)
Completed
- Kidney Cancer
- ipilimumab
-
Bethesda, MarylandWarren Grant Magnuson Clinical Center - NCI Clinical Studies Sup
Mar 14, 2012
Melanoma Trial (Ipilimumab, Interferon, Interleukin-2 (Aldesleukin))
Withdrawn
- Melanoma
- Ipilimumab
- +2 more
- (no location specified)
Jan 25, 2012
Metastatic Melanoma (Stage IIIC Non-résécable or no Surgically Curable or Stage IV With Classification AJCC) Trial in Nice,
Unknown status
- Metastatic Melanoma (Stage IIIC Non-résécable or no Surgically Curable or Stage IV With Classification AJCC)
- Metformin Group
-
Nice, Alpes-Maritimes, France
- +1 more
Apr 23, 2013
Melanoma, Metastases Trial in Worldwide (MDX-010 (anti-CTLA4) mAb, MDX-1379 (gp100) Melanoma Peptide Vaccine)
Completed
- Melanoma
- Metastases
- MDX-010 (anti-CTLA4) monoclonal antibody
- MDX-1379 (gp100) Melanoma Peptide Vaccine
-
Tucson, Arizona
- +208 more
Jun 29, 2011
Prostate Cancer Trial in United States (MDX-010 / MDX-010 + Docetaxel)
Completed
- Prostate Cancer
- MDX-010 / MDX-010 + Docetaxel
-
Tucson, Arizona
- +10 more
Jun 23, 2011
Melanoma Trial in United States (MDX-010 (CTLA-4))
Completed
- Melanoma
- MDX-010 (CTLA-4)
-
Tucson, Arizona
- +8 more
Jan 20, 2011
Melanoma Trial in Worldwide (ipilimumab (MDX-010, BMS-734016), Ipilimumab)
Completed
- Melanoma
- ipilimumab (MDX-010, BMS-734016)
- Ipilimumab
-
Tucson, Arizona
- +61 more
Feb 27, 2010
Long-term Data Collection for Subjects in MDX-010 Studies
Completed
- Metastatic Melanoma
-
Tuscon, Arizona
- +10 more
Apr 23, 2010
Malignant Melanoma Trial in United States (MDX-010)
Completed
- Malignant Melanoma
- MDX-010
-
Tucson, Arizona
- +3 more
Apr 23, 2010